NEW YORK (
) hit a new 52-week low Monday as it is currently trading at $33.10, below its previous 52-week low of $33.45 with 331,159 shares traded as of 10:55 a.m. ET. Average volume has been 204,800 shares over the past 30 days.
Integra LifeSciences has a market cap of $1 billion and is part of the
industry. Shares are down 19.7% year to date as of the close of trading on Friday.
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company has a P/E ratio of 23.4, below the average health services industry P/E ratio of 23.5 and above the S&P 500 P/E ratio of 17.7.
- Practice your IART trading strategies and win cash in our stock game.
TheStreet Ratings rates Integra LifeSciences as a
. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, deteriorating net income and disappointing return on equity. You can view the full
or get investment ideas from our